Performance of the VERSANT ® HIV-1 Resistance Assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes
In this study we evaluated the performance of the VERSANT ® HIV-1 Resistance Assays (LiPA) in detecting drug resistance in therapy-naive HIV-infected patients diagnosed in Belgium in 2000. We compared the results with population sequencing and found concordance to be in line with previous studies in...
Saved in:
Published in | FEMS immunology and medical microbiology Vol. 39; no. 2; pp. 119 - 124 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article Web Resource |
Language | English |
Published |
Oxford, UK
Elsevier B.V
28.11.2003
Blackwell Publishing Ltd Elsevier Science Bv |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | In this study we evaluated the performance of the VERSANT
® HIV-1 Resistance Assays (LiPA) in detecting drug resistance in therapy-naive HIV-infected patients diagnosed in Belgium in 2000. We compared the results with population sequencing and found concordance to be in line with previous studies in treatment-experienced patients (86.87% for reverse transcriptase (RT); 92.77% for protease (PRO)). Discordance was mainly due to indeterminate reactions on LiPA (8.45% for RT; 6.85% for PRO) and minor discordances (4.13% for RT; 0.25% for PRO). Major discordances were rare (0.46% for RT; 0.12% for PRO). Indeterminate reactions were significantly associated with strains belonging to non-B subtypes. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 scopus-id:2-s2.0-0242558933 |
ISSN: | 0928-8244 1574-695X |
DOI: | 10.1016/S0928-8244(03)00240-2 |